56 results about "Limb ischemia" patented technology

A multilumen catheter that maximizes the blood flow into and out of the patient's vasculature while also providing for passive and / or active perfusion of tissue downstream of where the catheter resides in the vasculature. The inventive catheter comprises a proximal end, a first distal and a second distal end. Lumens extending from the proximal end to each of these distal ends provide for blood circulation within one or between two blood vessels. At least one aperture in one of the lumens positioned near the proximal end provides for active perfusion of blood to the patient's vasculature downstream of where the aperture resides in the vasculature when the catheter is inserted into the patient for treatment. The inventive catheter may comprise a third lumen positioned entirely within the patient's vasculature, providing passive perfusion of blood to the patient's vasculature downstream of where the third lumen resides in the vasculature when the catheter is inserted into the patient for treatment.

A multilumen catheter that maximizes the blood flow into and out of the patient's vasculature while also providing for passive and / or active perfusion of tissue downstream of where the catheter resides in the vasculature. The inventive catheter comprises a proximal end, a first distal and a second distal end with first and second lumens extending from the proximal end to each of these distal ends to provide for blood circulation within one blood vessel or between two different blood vessels. The second lumen, and any additional lumens so desired, may be positioned coaxially with or radially around the first lumen. Redirecting means is provided at a distal end of at least one of said lumens for directing blood in a direction generally opposite of the direction of flow through said lumen.

A multilumen catheter that maximizes the blood flow into and out of the patient's vasculature while also providing for passive and / or active perfusion of tissue downstream of where the catheter resides in the vasculature. The inventive catheter comprises a proximal end, a first distal and a second distal end with first and second lumens extending from the proximal end to each of these distal ends to provide for blood circulation within one blood vessel or between two different blood vessels. The second lumen, and any additional lumens so desired, may be positioned coaxially with or radially around the first lumen. Redirecting means is provided at a distal end of at least one of said lumens for directing blood in a direction generally opposite of the direction of flow through said lumen.

The invention discloses a multifunctional blood vessel compression hemostasis device which comprises a bandage, an air cushion, a liquid sensor, sponge, a connecting pipe, an injection pipe, an injector, an air inlet pipe, a timer, snap ring and a warner. The multifunctional blood vessel compression hemostasis device is ingenious in structure, powerful in function and simple to operate; by using the device, effective dot oppression can be performed on a patient's blood vessel puncture part, local compression force is added under the same pressure, and a compression hemostasis effect is improved; pressure applied to a puncture point can further be measured and controlled accurately, pressure values are adjusted according to different patients, a sound alarm is given against local bleeding, complications such as bleeding of the puncture position, far-end limb ischemia and internal fistula blockage are avoided, and the patients' prognosis is improved. By using the device, local compression time can be preset, the complications caused by improper compression time are avoided, and medical workers' working efficiency is improved.

A multilumen catheter that maximizes the blood flow into and out of the patient's vasculature while also providing for passive and / or active perfusion of tissue downstream of where the catheter resides in the vasculature. The inventive catheter comprises a proximal end, a first distal and a second distal end with first and second lumens extending from the proximal end to each of these distal ends to provide for blood circulation within one blood vessel or between two different blood vessels. The second lumen, and any additional lumens so desired, may be positioned coaxially with or radially around the first lumen. Redirecting means is provided at a distal end of at least one of said lumens for directing blood in a direction generally opposite of the direction of flow through said lumen.

A system and method for treating critical limb ischemia (CLI) including a radiopaque micro stent disposed for cross ankle stenting as well as retrograde pedal / tibial artery access, in conjunction with antegrade access for the recanalization of impaired tibial vessels. A radiopaque medical device is constructed from a tubular-shaped body having a thin wall defining a specific strut pattern. In an additional aspect, the present apparatus introduces a new radiopaque medical device, such as a stent, wherein the tubular body includes a super elastic, nickel-titanium (nitinol) alloy.

Disclosed are cellular compositions and methods for preventing, treating or reducing the severity of tissue ischemia, particularly limb ischemia in a mammal. One inventive method includes administering a therapeutically effective amount of a cellular composition comprising a novel isolated multi-potent human bone marrow-derived stem cell (BMSC) having undetectable or negligible levels of markers of other known stem cells isolated from bone marrow. These cells can be expanded in vitro and formulated into cellular compositions and grafts capable of differentiating into components of functional new blood vessels when directly administered into ischemic limb tissue.

A multilumen catheter that maximizes the blood flow into and out of the patient's vasculature while also providing for passive and / or active perfusion of tissue downstream of where the catheter resides in the vasculature. The inventive catheter comprises a proximal end, a first distal and a second distal end with first and second lumens extending from the proximal end to each of these distal ends to provide for blood circulation within one blood vessel or between two different blood vessels. The second lumen, and any additional lumens so desired, may be positioned coaxially with or radially around the first lumen. Redirecting means is provided at a distal end of at least one of said lumens for directing blood in a direction generally opposite of the direction of flow through said lumen.

A multilumen catheter that maximizes the blood flow into and out of the patient's vasculature while also providing for passive and / or active perfusion of tissue downstream of where the catheter resides in the vasculature. The inventive catheter comprises a proximal end, a first distal and a second distal end with first and second lumens extending from the proximal end to each of these distal ends to provide for blood circulation within one blood vessel or between two different blood vessels. The second lumen, and any additional lumens so desired, may be positioned coaxially with or radially around the first lumen. Redirecting means is provided at a distal end of at least one of said lumens for directing blood in a direction generally opposite of the direction of flow through said lumen.

A method of quantifying crucial limb ischemia, the method including the steps of: acquiring temperature data over time of a wound using LWIT; creating a database of the acquired temperature data; comparing the data of the created database to known Heterogeneity Indices; and evaluating the comparisons to assess wound healing.

The utility of pulse volume measurement is expanded to detection of many conditions which have previously not been detected or have been detected using more complicated techniques. Such conditions include blood loss, septic shock, cardiogenic shock, neonatal sepsis, patent ductus arteriosus, limb ischemia, intra-aortic balloon pump performance, peripheral vascular disease, congestive heart failure, the effectiveness of vasoactive medications, syncope, dehydration, pre-eclampsia, deep vein thrombosis, thermal injuries, vascular instability due to renal dialysis, compromising of circulation to the hand caused by radial artery harvesting, changes in cardiac output, and hypertension. According to the present invention, such diagnoses can be performed by taking one measurement, by taking measurements over time to detect a change or by taking measurements before and after application of a treatment or stimulus.

A method for modulating vasculogenesis or arteriogenesis or angiogenesis, especially for treating heart and limb ischemia, using the core domain protein of PDGF-C, a new member of the PDGF / VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.

The invention discloses the application of S1P in preparing a medicament for inhibiting mesenchymal stem cells from apoptosis, in preparing a medicament for curing ischemic heart disease and a medicament for curing limb ischemia. The invention can significantly improve the survival rate of mesenchymal stem cells in clinical transplantation.

The invention discloses a limb ischemia therapeutic instrument and a control method of the limb ischemia therapeutic instrument. The limb ischemia therapeutic instrument is mainly used for preventing or treating atherosclerosis, the mode of carrying out intelligent operation and selecting preset parameters according to systolic pressure of a user is adopted to work, and the defect of an existing limb ischemia therapeutic instrument can be effectively overcome. The limb ischemia therapeutic instrument comprises a sleeve belt, a sleeve belt pressure module, a control module and a power supply, and further comprises a detecting module. The detecting module is arranged on the sleeve belt and is connected with the control module and used for detecting the systolic pressure of the user and sending the systolic pressure to the control module. The sleeve belt pressure module is connected with the sleeve belt and the control module, and is used for inflating or deflating the sleeve belt according to the control instruction of the control module. The control module is used for controlling the sleeve belt pressure module according to the systolic pressure and the preset parameters.

The present invention uses neural stem cells in the manufacture of a medicament for the treatment of a patient suffering peripheral arterial disease. The invention is particularly suited for treating limb ischemia or Buerger's disease.

The present invention provides methods for treating ischemic diseases, which comprise the step of administering angiopoietin-1 (Ang1) or an Ang1-encoding vector. The present invention also provides ischemic disease treatment kits which comprise Ang1. Ang1-expressing vectors were prepared, and each was administered alone intramyocardially to rats in the acute phase of myocardial infarction to express Ang1 in the local cardiac muscle. The results indicate that marked effects have been obtained, such as decrease in post-infarction mortality rate, increase in blood vessel number in myocardium, reduction of myocardial infarct size, and improvement of cardiac function. Administration of the required VEGF was not necessary for the angiogenic activity of Ang1. Furthermore, when an Ang1viral expression vector was administered alone to an animal model of severe limb ischemia, in which ischemia had been induced by arterial ligation, a remarkable limb salvage effect was obtained. The Ang1 gene therapy is excellent as a safe and effective therapeutic method for ischemic diseases such as ischemic heart diseases and limb ischemia.

The invention discloses an application of hydrogen in preparation of a drug for preventing limb ischemia-reperfusion injury. Experimental results show that hydrogen can remarkably reduce rise of limb ischemia-reperfusion MDA (malondialdehyde) and 8-isoprostanes F2alpha (8-iso-PGF2alpha), protect the activity of SOD (superoxide dismutase) and GSH-Px (glutathione peroxidase), reduce lipid peroxidation, protect histocyte structure and function integrity, effectively protect tissue injury caused by limb ischemia-reperfusion and has great significance for clinical prevention and treatment of the limb ischemia-reperfusion injury.

The invention relates to a tourniquet buckle with a timing function. The tourniquet buckle comprises a mechanical timer, an external buckle body, an internal buckle body and a tourniquet constraint band fixed on the external buckle body, wherein the external buckle body is provided with a constraint band external through hole, the internal buckle body comprises a compression block, a displacement protruding block and a manual pressing block, the compression block is provided with a constraint band internal through hole, and the mechanical timer comprises a time panel, a pointer, a winding mechanism and a winding mechanism rotary shaft; when the pointer of the mechanical timer is located at the zero line on the time panel (loosened state), a disc protrusion is abutted against the displacement protruding block, the constraint band internal through hole is communicated with the constraint band external through hole, and springs are in a contraction state; when the pointer is located at the non-zero line on the time panel (buckled state), the disc protrusion does not contact with the displacement protruding block, the constraint band internal hole and the constraint band external hole are staggered, and the springs are in a natural state. The tourniquet buckle has the advantages that the tourniquet can be loosened in a timed manner, and accidents of limb ischemia or limb necrosis of infant patients due to the fact that the tourniquet is forgotten to be loosened can be avoided effectively.

The invention discloses an application of icariin in preparation of a medicine for promoting angiogenesis. The icariin is used for preparing the medicine for promoting angiogenesis. Animal experimental verification proves that the prepared medicine composition can be used for preventing and treating ischemic injuries including perpetual ischemic injuries and ischemia-reperfusion injuries of limbs and intestinal tracts (small intestines and large intestines). The icariin has the advantages of being wide in source of raw materials, easy to obtain, simple and practical in preparation of the medicine and having a good curative effect.

The invention relates to a construction method of a liver injury animal model after limb ischemia reperfusion, which comprises the following steps: taking 10 SPF-grade SD (Sprague Dawley) rats with the weight of 150-200g, feeding the rats for one week, and forbidding water 2 hours before modeling. The method comprises the following steps: performing intraperitoneal anesthesia on a rat by using 1% pentobarbital sodium (25mg / kg), constraining four limbs and the head on a self-made rat plate, removing hair from a left rear leg, cerclaging a tourniquet at the root of a thigh, blocking for 2 hours, loosening the tourniquet, continuing for 6 hours, sampling 5mL of blood from the heart, centrifuging whole blood, sub-packaging serum, and storing at-20 DEG C. And detecting ALT, AST, SOD, MDA and GSH indexes of serum. Laparotomy is carried out to take the liver, the liver is put into frozen normal saline to be repeatedly rinsed, and finally the liver index is calculated. The method has the beneficial effects that the modeling time is short, the success rate is high, and the replicability is good; the method is applied to a series of disaster medical researches, has a wide application prospect, and can generate good social benefits, economic benefits and scientific research values.

The invention relates to an axillary artery and femoral artery cannula without a perfusion ischemia area and application of the cannula. The axillary artery and femoral artery cannula comprises a cannula main body of a blood supply end; the axillary artery and femoral artery cannula is characterized by further comprising a proximal end tube and a distal end tube, the two of which are communicated with the cannula main body and have shunting and pressure dividing effects, and a plastic extracorporeal circulating perfusion tube which is formed on the overall structure and formed into a T-shaped or Y-shaped structure, wherein an included angle is formed between the proximal end tube of the perfusion tube of the Y-shaped structure and the cannula main body of the blood supply end so that the perfusion blood flow can be distributed or regulated. The axillary artery and femoral artery cannula without the perfusion ischemia area is applied to the axillary artery and the femoral artery on the right side to realize arterial perfusion of the whole body and selective cerebral perfusion of deep hypothermic circulatory arrest during extracorporeal circulation, and meanwhile, the ischemia of the right upper limb and the right lower limb can be avoided; obviously, the axillary artery and femoral artery cannula without the ischemia area is capable of realizing the distribution and control of the perfusion blood flow, and no perfusion ischemia area is formed during extracorporeal circulation; besides, the axillary artery and femoral artery cannula is convenient to operate and high in universality; the operation time can be greatly reduced so that the limb ischemia time can be reduced; in short, the axillary artery and femoral artery cannula without the perfusion ischemia area can be widely applied.

The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS / brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina.

The invention provides a perfusion-type aorta blocking double-balloon. The perfusion-type aorta blocking double-balloon has the advantages that by the sectional-type double-balloon, a first balloon islocated in an upper half portion region between the lower edge of the left subclavian artery and the celiac trunk, so that the near-end aorta can be blocked, and hemorrhage can be controlled to the greatest extent; a second balloon is located in a lower half portion region between the lower edge of the renal artery and the iliac artery bifurcation, so that hemorrhage between the celiac trunk andthe renal artery is blocked, and vital organs such as bilateral lower limbs are perfused selectively; selective liquid perfusion to related damage-free regions is realized, and the problem of ischemiaof visceral organs and limbs is solved.